Treatment Development Program Clinical Trials
1. Patch-type Alopecia Areata Participants Sought for Study of Intralesional Steroids
Intralesional steroids are the most commonly used treatment for alopecia areata, yet much remains unknown about the risks and benefits of different doses of intralesional steroids. The goal of this study is to answer some of those questions.
New York Presbyterian Hospital at Columbia University Department of Dermatology is seeking men & women, at least 18 years old, to participate in a research study of intralesional injections of steroids versus inactive saline (salt water) for the treatment of Alopecia areata.
Those who qualify should be diagnosed with patch-type alopecia areata with 50% or less hair loss and episodes lasting from 3 to 12 months in duration.
Study participants would have monthly visits for scalp and hair examinations and scalp injections. Scalp biopsies and blood draws would occur at the first visit, week 4, week 12, and week 24.
Injection groups will be randomly assigned to intralesional triamcinolone 2.5mg injections (IL-TAC), IL-TAC 5mg injections, IL-TAC 10mg injections, or saline (placebo) injections. Injections occur every 4 weeks for 6 months.
There will be a 6 month follow up after the treatment period of 6 months for a total of 12 months study duration. During the follow up period, participants will be seen every 6 weeks and examined for hair loss/growth. Participants that did not experience regrowth of hair during the treatment period may be offered either IL-TAC 2.5mg, 5mg or 10mg if deemed appropriate by the study physician(s).
Contact: Department of Dermatology Clinical Research Unit at 1.212.305.6953 or email@example.com
NAAF provides research notices as an informational service to its members. NAAF is not conducting the study. This information does not represent a NAAF endorsement, but rather makes you aware that clinical studies are available for your participation if you choose. If you are presently under the care of a physician for alopecia areata, or other conditions, you should discuss this study with your doctor before altering your treatment program. NAAF is not responsible for any adverse outcomes.
ClinicalTrials.gov offers up-to-date information for locating federally and privately supported clinical trials for a wide range of diseases and conditions. A clinical trial (also clinical research) is a research study in human volunteers to answer specific health questions. Interventional trials determine whether experimental treatments or new ways of using known therapies are safe and effective under controlled environments. Observational trials address health issues in large groups of people or populations in natural settings.
Visit this website to review clinical trials that are enrolling around the country on alopecia areata and other diseases.
Dr. Maria Hordinsky, at the University of Minnesota is conducting a study examining the relationship between a commonly utilized treatment for alopecia areata, Kenalog-10 intralesional injections in combination with a filler
Otherwise healthy patients diagnosed with alopecia areata with over 50% of scalp involvement will be eligible for enrollment in this study. Those enrolled will undergo intralesional Kenalog-10 (triamcinolone acetonide10mg/mL) and filler injections every 6 weeks for a period 12 weeks. This period will be followed by a 6 injection-free, follow-up visit. This study will advance the understanding of the effects of this highly utilized therapy in combination with a filler.
For more information or if you would like to be involved, please contact the University of Minnesota Department of Dermatology:
NAAF provides research notices as an informational service to its members. This information does not represent a NAAF endorsement, but rather makes you aware that clinical studies are available for your participation if you choose. If you are presently under the care of a physician for alopecia areata, or other conditions, you should discuss this study with your doctor before altering your treatment program.